QUTENZA

Peak

capsaicin

NDATOPICALPATCH
Approved
Nov 2009
Lifecycle
Peak
Competitive Pressure
8/100
Clinical Trials
19

Clinical Trials (5)

NCT03074162Phase 1Completed

Comparison of the Bioavailability of Diclofenac in a Combination Product (Diclofenac 2% + Capsaicin 0.075% Topical Gel) With Two Diclofenac Only Products, Diclofenac Mono Gel 2% and Voltarol® 12 Hour Emulgel 2.32% Gel, in Healthy Volunteers

Started Apr 2017
48 enrolled
Healthy
NCT02700815Phase 3Completed

Capsaicin + Diclofenac Gel in Acute Back Pain or Neck Pain

Started May 2016
746 enrolled
Acute Pain
NCT02570841Phase 4Completed

Pain Thresholds Under High-dose Topical Capsaicin

Started Feb 2015
20 enrolled
Pain
NCT02171182N/ACompleted

A Study of Efficacy and Safety of Qutenza in Patients With Post-operative Peripheral Neuropathic Pain

Started Jan 2014
319 enrolled
Post-operative Peripheral Neuropathic Pain
NCT01797796Phase 1Completed

Effect Of PF-06305591 On Capsaicin And Capsaicin/Heat-Induced Neurogenic Flare

Started Apr 2013
16 enrolled
Healthy

Loss of Exclusivity

LOE Date
Mar 26, 2030
49 months away
Patent Expiry
Mar 26, 2030

Patent Records (2)

Patent #ExpiryTypeUse Code
9226903
Dec 15, 2028
Product
8821920
Mar 26, 2030
Product